Scientific publications 

Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor

Fernández-Galar M., España A., López-Picazo J.M. [SP]
Departments of Dermatology and *Oncology, University Clinic of Navarra, Pamplona, Spain.

Magazine: Clinical and Experimental Dermatology

Date: Mar 1, 2004

Medical Oncology Dermatology

Drugs that inhibit the epidermal growth factor receptor, such as ZD1839 or C225, are being used increasingly in the treatment of solid tumours.

This has led to the appearance of new secondary effects. We describe the case of a patient who presented with an acneiform eruption secondary to the administration of ZD1839. These lesions healed in a few days after stopping the drug.

CITATION  Clin Exp Dermatol. 2004 Mar;29(2):138-40

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra